Role of induced pluripotent stem cells in diagnostic cardiology

Abstract

Ethical concerns about stem cell-based research have delayed important advances in many areas of medicine, including cardiology. The introduction of induced pluripotent stem cells (iPSCs) has supplanted the need to use human stem cells for most purposes, thus eliminating all ethical controversies. Since then, many new avenues have been opened in cardiology research, not only in approaches to tissue replacement but also in the design and testing of antiarrhythmic drugs. This methodology has advanced to the point where induced human cardiomyocyte cell lines can now also be obtained from commercial sources or tissue banks. Initial studies with readily available iPSCs have generally confirmed that their behavioral characteristics accurately predict the behavior of beating cardiomyocytes in vivo . As a result, iPSCs can provide new ways to study arrhythmias and heart disease in general, accelerating the development of new, more effective antiarrhythmic drugs, clinical diagnoses, and personalized medical care. The focus on producing cardiomyocytes that can be used to replace damaged heart tissue has somewhat diverted interest in a host of other applications. This manuscript is intended to provide non-specialists with a brief introduction and overview of the research carried out in the field of heart rhythm disorders.

Extracellular Vesicles as Theranostic Tools in Kidney Disease

“…Induced pluripotent stem cells (iPSCs) are produced by reprogramming adult mesenchymal cells that can differentiate into various lineages, including mesenchymal stem cells. Importantly, although tissue-specific mesenchymal stem cells can be safely passaged to few generations, iPSCs can renew numerous times (84). Therefore, iPSC mesenchymal stem cell extracellular vesicles are receiving escalating attention in regenerative therapy.…”

Pancreatic transplant surgery and stem cell therapy: Finding the balance between therapeutic advances and ethical principles

“…Despite some still undefined regulatory and technological aspects, a prospect of certain usefulness in terms of improving access to care is represented by biobanking; the deve lopment of banks with large-scale storage represents a means to obtain the amplification of cellular reserves, the reduction of treatment costs, and ultimately the therapeutic possibilities for patients[ 77 - 79 ]. In parallel to what has been stated so far, the use of stem cells for the creation of experimental models of T1DM can certainly guarantee the personalization and accessibility to pharmacological treatments of higher quality and safety in the phase before replacement therapy[ 80 ].…”